These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1125 related articles for article (PubMed ID: 33547593)

  • 21. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation.
    Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S
    mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.
    Li YC; Bai WZ; Hashikawa T
    J Med Virol; 2020 Jun; 92(6):552-555. PubMed ID: 32104915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection.
    Rathnasinghe R; Strohmeier S; Amanat F; Gillespie VL; Krammer F; García-Sastre A; Coughlan L; Schotsaert M; Uccellini MB
    Emerg Microbes Infect; 2020 Dec; 9(1):2433-2445. PubMed ID: 33073694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroinvasive potential of a primary respiratory pathogen SARS- CoV2: Summarizing the evidences.
    Lahiri D; Mondal R; Deb S; Bandyopadhyay D; Shome G; Sarkar S; Biswas SC
    Diabetes Metab Syndr; 2020; 14(5):1053-1060. PubMed ID: 32640417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians.
    Maury A; Lyoubi A; Peiffer-Smadja N; de Broucker T; Meppiel E
    Rev Neurol (Paris); 2021; 177(1-2):51-64. PubMed ID: 33446327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Animal Models of COVID-19. I. Comparative Virology and Disease Pathogenesis.
    Zeiss CJ; Compton S; Veenhuis RT
    ILAR J; 2021 Dec; 62(1-2):35-47. PubMed ID: 33836527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LY6E impairs coronavirus fusion and confers immune control of viral disease.
    Pfaender S; Mar KB; Michailidis E; Kratzel A; Boys IN; V'kovski P; Fan W; Kelly JN; Hirt D; Ebert N; Stalder H; Kleine-Weber H; Hoffmann M; Hoffmann HH; Saeed M; Dijkman R; Steinmann E; Wight-Carter M; McDougal MB; Hanners NW; Pöhlmann S; Gallagher T; Todt D; Zimmer G; Rice CM; Schoggins JW; Thiel V
    Nat Microbiol; 2020 Nov; 5(11):1330-1339. PubMed ID: 32704094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivated SARS-CoV-2 Vaccine Shows Cross-Protection against Bat SARS-Related Coronaviruses in Human ACE2 Transgenic Mice.
    Liu MQ; Jiang RD; Guo J; Chen Y; Yang DS; Wang X; Lin HF; Li A; Li B; Hu B; Wang ZJ; Yang XL; Shi ZL
    J Virol; 2022 Apr; 96(8):e0016922. PubMed ID: 35343762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice.
    Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Mouse Model of MHV-1 Virus Infection for Study of Acute and Long COVID Infection.
    Masciarella AD; Di Gregorio DM; Ramamoorthy R; Hussain H; Jayakumar AR; Paidas MJ
    Curr Protoc; 2023 Oct; 3(10):e896. PubMed ID: 37867460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries.
    Román GC; Spencer PS; Reis J; Buguet A; Faris MEA; Katrak SM; Láinez M; Medina MT; Meshram C; Mizusawa H; Öztürk S; Wasay M;
    J Neurol Sci; 2020 Jul; 414():116884. PubMed ID: 32464367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adaptation of SARS-CoV-2 to ACE2
    Li K; Verma A; Li P; Ortiz ME; Hawkins GM; Schnicker NJ; Szachowicz PJ; Pezzulo AA; Wohlford-Lenane CL; Kicmal T; Meyerholz DK; Gallagher T; Perlman S; McCray PB
    J Virol; 2024 Jan; 98(1):e0151023. PubMed ID: 38168680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection.
    Lavi E; Cong L
    Exp Mol Pathol; 2020 Aug; 115():104474. PubMed ID: 32454103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myoclonus status revealing COVID 19 infection.
    Ben Mohamed D; Zouari R; Ketata J; Nabli F; Blel S; Ben Sassi S
    Seizure; 2023 Jan; 104():12-14. PubMed ID: 36446232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports.
    Najjar S; Najjar A; Chong DJ; Pramanik BK; Kirsch C; Kuzniecky RI; Pacia SV; Azhar S
    J Neuroinflammation; 2020 Aug; 17(1):231. PubMed ID: 32758257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toll-like receptor 4 deficiency increases disease and mortality after mouse hepatitis virus type 1 infection of susceptible C3H mice.
    Khanolkar A; Hartwig SM; Haag BA; Meyerholz DK; Harty JT; Varga SM
    J Virol; 2009 Sep; 83(17):8946-56. PubMed ID: 19553337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.